{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:14:17Z","timestamp":1794266057184,"version":"4.9.0"},"reference-count":36,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This study was funded by Johnson & Johnson.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2026,8,17]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To describe haemolytic disease outcomes, growth, neurodevelopment and health-related quality of life (HRQoL) through 24 months of life in infants exposed to nipocalimab in pregnancies at high risk of early-onset severe haemolytic disease of the fetus and newborn (EOS-HDFN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A multicentre, open-label, single-arm trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Centres with expertise in HDFN management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Pregnant individuals with previous EOS-HDFN and maternal anti-D titres \u226532\u2009or anti-K titres \u22654.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Weekly nipocalimab (30 and\/or 45 mg\/kg) from 14 to 35\u2009gestational weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Infants\u2019 cord-blood alloantibody titres at birth, HDFN management, growth through 6 months, neurodevelopment (caregiver-reported Ages and Stages Questionnaire, third edition (ASQ-3)) and HRQoL assessments through 24 months of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 13 pregnancies, 12 resulted in live births; one fetal loss occurred due to intrauterine transfusion (IUT) complications. A single simple transfusion was administered in one of seven infants delivered after a maternal nipocalimab course without IUTs, where cord blood alloantibody titres were &lt;8. Multiple transfusions (one to seven\u2009simple transfusions\/infant; one exchange transfusion) were administered to five infants delivered after early nipocalimab discontinuation and IUTs, with cord-blood alloantibody titres ranging from 512 to 32 768. No unusual growth patterns were observed through 6 months. No neurodevelopmental delays were identified through 24 months of life, with mean ASQ-3 domain scores within normal ranges. HRQoL outcomes were positive across physical, emotional, social and cognitive functioning.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maternal nipocalimab in pregnancies at high risk of EOS-HDFN may reduce adverse neonatal outcomes correlating with low cord-blood alloantibody titres, without affecting growth through 6 months, neurodevelopment or HRQoL through 24 months of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03842189\">NCT03842189<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/archdischild-2026-331009","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:20:19Z","timestamp":1788801619000},"page":"fetalneonatal-2026-331009","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Paediatric outcomes after maternal nipocalimab for haemolytic disease of the fetus and newborn: an open-label, single-arm study"],"prefix":"10.1136","clinical-trial-number":[{"clinical-trial-number":"nct03842189","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03842189","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05912517","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03842189","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05912517","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4820-143X","authenticated-orcid":false,"given":"Derek P","family":"de Winter","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology, Willem-Alexander Children\u2019s Hospital, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Kenneth J","family":"Moise","sequence":"additional","affiliation":[{"name":"Dell Medical School, The University of Texas at Austin, Austin, Texas, USA"},{"name":"Comprehensive Fetal Care Center at Dell Children\u2019s Medical Center, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona E","family":"Ling","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Oepkes","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonor","family":"Tiblad","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E J T Joanne","family":"Verweij","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Smoleniec","sequence":"additional","affiliation":[{"name":"Feto-Maternal Unit, Liverpool Hospital, Liverpool, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich J","family":"Sachs","sequence":"additional","affiliation":[{"name":"Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany"},{"name":"Department of Thrombosis and Hemostasis, Giessen University Hospital, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Bein","sequence":"additional","affiliation":[{"name":"Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9987-4223","authenticated-orcid":false,"given":"Mark D","family":"Kilby","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, UK"},{"name":"Fetal Medicine Center, Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell S","family":"Miller","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Devlieger","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University Hospitals KU Leuven, Leuven, Belgium"},{"name":"Department of Obstetrics, Gynecology and Fertility, GZA Campus Sint-Augustinus, Wilrijk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Debeer","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Universitair Ziekenhuis Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn H","family":"Leu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Nelson","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Smith","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa B","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Raritan, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Lee","family":"Tjoa","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumyla","family":"Saeed-Khawaja","sequence":"additional","affiliation":[{"name":"Johnson & Johnson, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3513-5066","authenticated-orcid":false,"given":"Enrico","family":"Lopriore","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology, Willem-Alexander Children\u2019s Hospital, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026090710201311000_archdischild-2026-331009v1.1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjh.17041","article-title":"Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation","volume":"192","author":"Castleman","year":"2021","journal-title":"Br J Haematol"},{"key":"2026090710201311000_archdischild-2026-331009v1.2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54330","article-title":"Variations and Opportunities in Postnatal Management of Hemolytic Disease of the Fetus and Newborn","volume":"8","author":"de Winter","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026090710201311000_archdischild-2026-331009v1.3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/uog.17319","article-title":"Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures","volume":"50","author":"Zwiers","year":"2017","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2026090710201311000_archdischild-2026-331009v1.4","doi-asserted-by":"crossref","DOI":"10.1186\/s12884-025-07208-9","article-title":"Patient experience and burden of haemolytic disease of the foetus and newborn: a systematic review","volume":"25","author":"Maurice","year":"2025","journal-title":"BMC Pregnancy Childbirth"},{"key":"2026090710201311000_archdischild-2026-331009v1.5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000362812","article-title":"Intrauterine blood transfusion: current indications and associated risks","volume":"36","author":"Lindenburg","year":"2014","journal-title":"Fetal Diagn Ther"},{"key":"2026090710201311000_archdischild-2026-331009v1.6","doi-asserted-by":"crossref","first-page":"102119","DOI":"10.1016\/j.jogoh.2021.102119","article-title":"Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: a case-control study","volume":"50","author":"Maisonneuve","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2026090710201311000_archdischild-2026-331009v1.7","doi-asserted-by":"crossref","first-page":"291.e1\u2013291.e9","DOI":"10.1016\/j.ajog.2018.06.007","article-title":"Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn","volume":"219","author":"Zwiers","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"2026090710201311000_archdischild-2026-331009v1.8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bjh.15962","article-title":"Predicting anaemia and transfusion dependency in severe alloimmune haemolytic disease of the fetus and newborn in the first 3 months after birth","volume":"186","author":"Ree","year":"2019","journal-title":"Br J Haematol"},{"key":"2026090710201311000_archdischild-2026-331009v1.9","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17474086.2017.1331124","article-title":"Neonatal management and outcome in alloimmune hemolytic disease","volume":"10","author":"Ree","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"2026090710201311000_archdischild-2026-331009v1.10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.18170","article-title":"International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn","volume":"198","author":"Lieberman","year":"2022","journal-title":"Br J Haematol"},{"key":"2026090710201311000_archdischild-2026-331009v1.11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00431-022-04724-0","article-title":"History and current standard of postnatal management in hemolytic disease of the fetus and newborn","volume":"182","author":"De Winter","year":"2023","journal-title":"Eur J Pediatr"},{"key":"2026090710201311000_archdischild-2026-331009v1.12","article-title":"Immunoglobulin for alloimmune hemolytic disease in neonates","volume":"3","author":"Zwiers","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026090710201311000_archdischild-2026-331009v1.13","doi-asserted-by":"publisher","DOI":"10.2174\/1573396313666170815100214"},{"key":"2026090710201311000_archdischild-2026-331009v1.14","doi-asserted-by":"crossref","first-page":"141.e1\u2013141.e8","DOI":"10.1016\/j.ajog.2011.09.024","article-title":"Long-term neurodevelopmental outcome after intrauterine transfusion for hemolytic disease of the fetus\/newborn: the LOTUS study","volume":"206","author":"Lindenburg","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"2026090710201311000_archdischild-2026-331009v1.15","unstructured":"IMAAVY (nipocalimab-aahu) injection, for intravenous use. Horsham, PA: Janssen Biotech, Inc; 2025."},{"key":"2026090710201311000_archdischild-2026-331009v1.16","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1016\/S0140-6736(25)01430-8","article-title":"Efficacy and safety of nipocalimab in patients with moderate-to-severe Sj\u00f6gren\u2019s disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial","volume":"406","author":"Noaiseh","year":"2025","journal-title":"Lancet"},{"key":"2026090710201311000_archdischild-2026-331009v1.17","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004278","article-title":"Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"key":"2026090710201311000_archdischild-2026-331009v1.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314466"},{"key":"2026090710201311000_archdischild-2026-331009v1.19","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/a-2404-8089","article-title":"Design of a Phase 3, Global, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn","volume":"42","author":"Komatsu","year":"2025","journal-title":"Am J Perinatol"},{"key":"2026090710201311000_archdischild-2026-331009v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00498-8"},{"key":"2026090710201311000_archdischild-2026-331009v1.21","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500097","article-title":"Infant Immunity after Maternal Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn","volume":"5","author":"de Winter","year":"2026","journal-title":"NEJM Evid"},{"key":"2026090710201311000_archdischild-2026-331009v1.22","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2431-13-59","article-title":"A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants","volume":"13","author":"Fenton","year":"2013","journal-title":"BMC Pediatr"},{"key":"2026090710201311000_archdischild-2026-331009v1.23","first-page":"5","article-title":"Ages and Stages Questionnaire: a global screening scale","volume":"74","author":"Singh","year":"2017","journal-title":"Bol Med Hosp Infant Mex"},{"key":"2026090710201311000_archdischild-2026-331009v1.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9730-5"},{"key":"2026090710201311000_archdischild-2026-331009v1.25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jped.2022.04.004","article-title":"Use of prophylactic phototherapy for RhD neonatal disease in a referral service","volume":"99","author":"Rodrigues","year":"2023","journal-title":"J Pediatr (Rio J)"},{"key":"2026090710201311000_archdischild-2026-331009v1.26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ebch.1898","article-title":"Cochrane Review: prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants","volume":"8","author":"Okwundu","year":"2013","journal-title":"Evid Based Child Health"},{"key":"2026090710201311000_archdischild-2026-331009v1.27","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.302"},{"key":"2026090710201311000_archdischild-2026-331009v1.28","doi-asserted-by":"crossref","first-page":"105081","DOI":"10.1016\/j.earlhumdev.2020.105081","article-title":"Evaluation of the Ages and Stages Questionnaire (ASQ 3) as a developmental screener at 9, 18, and 24 months","volume":"147","author":"Agarwal","year":"2020","journal-title":"Early Hum Dev"},{"key":"2026090710201311000_archdischild-2026-331009v1.29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pedneo.2023.03.013","article-title":"Concurrent validity of the ages and stages questionnaires with Bayley Scales of Infant Development-III at 2 years - Singapore cohort study","volume":"65","author":"Agarwal","year":"2024","journal-title":"Pediatr Neonatol"},{"key":"2026090710201311000_archdischild-2026-331009v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.03.044"},{"key":"2026090710201311000_archdischild-2026-331009v1.31","unstructured":"Ages & Stages Questionnaires . Considerations when screening premature children. 2018. Available: https:\/\/agesandstages.com\/wp-content\/uploads\/2018\/08\/Considerations-when-screening-premature-children.pdf [Accessed 22 Aug 2025]."},{"key":"2026090710201311000_archdischild-2026-331009v1.32","unstructured":"Bayley-III Clinical Use and Interpretation. 3rd edn. Academic Press, 2010:1\u2013240."},{"key":"2026090710201311000_archdischild-2026-331009v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)80061-3"},{"key":"2026090710201311000_archdischild-2026-331009v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.12.012"},{"key":"2026090710201311000_archdischild-2026-331009v1.35","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2008.143560"},{"key":"2026090710201311000_archdischild-2026-331009v1.36","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/S2352-3026(25)00030-4","article-title":"Long-term neurodevelopmental outcomes in infants with haemolytic disease of the newborn treated with darbepoetin","volume":"12","author":"de Winter","year":"2025","journal-title":"Lancet Haematol"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2026-331009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:20:22Z","timestamp":1788801622000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2026-331009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":36,"alternative-id":["10.1136\/archdischild-2026-331009"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2026-331009","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]}}}